Standardized high-performance peptide APIs, synthetic GnRH analogs, cytoprotective peptides, and metabolic regulators synthesized via validated solid-phase synthesis platforms.
An in-depth review of synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro engineering, orthogonal protective chemistries, and critical quality attributes (CQAs).
Selank (CAS Registry Number 129954-34-3) is a synthetic heptapeptide sequence: H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH. Derived structurally from the endogenous immunomodulatory tetrapeptide Tuftsin (Thr-Lys-Pro-Arg) coupled with a C-terminal Pro-Gly-Pro tripeptide stabilizer, it presents distinct synthetic challenges due to multiple proline residues.
Proline introduction induces steric strain and secondary amine coupling hurdles during Fmoc-based Solid-Phase Peptide Synthesis (Fmoc-SPPS). Our facility deploys advanced uronium/phosphonium coupling reagents (HATU/HBTU/PyBOP) combined with microwave-assisted SPPS to ensure complete amino acid acylation without racemization.
Peptides synthesized by conventional acid-cleaved resins naturally retain trifluoroacetic acid (TFA) as a counter-ion. While acceptable for basic in-vitro assays, residual TFA exhibits significant cytotoxicity in cellular proliferation assays and regulatory non-compliance in preclinical in-vivo models.
Thinheal operates proprietary preparative ion-exchange chromatography systems using volatile ammonium acetate and dilute acetic acid washes. This quantitative exchange converts Selank TFA salts into ultra-pure Selank Acetate, maintaining residual TFA below 0.1% while preserving net peptide content between 80% and 88%.
The physical stability of synthetic Selank depends heavily on the controlled removal of bulk solvents during cyclic lyophilization. Moisture content above 5.0% acts as a plasticizer, inducing spontaneous deamidation, peptide aggregation, and peptide bond cleavage.
Our multi-stage shelf freeze-drying chambers operate under strictly monitored eutectic temperature profiles, achieving residual water content consistently <3.0% w/w. The resulting amorphous cake dissolves within 15 seconds in bacteriostatic water or sterile saline, exhibiting zero particulate precipitation.
Transparent wholesale pricing structures based on production batch scale, target purity metrics, salt form customization, and regulatory dossier support.
| Procurement Tier | Order Volume | Purity Grade (HPLC) | Counter-Ion | Packaging / Release Format | Reference Price (USD) | Lead Time |
|---|---|---|---|---|---|---|
| Preclinical Pilot | 1g – 10g | ≥ 98.0% | TFA / Acetate option | Sterile Sealed Vials (Lyophilized) | $45 – $75 / gram | 3 – 5 Days (In Stock) |
| Translational Batch | 50g – 250g | ≥ 98.5% | Acetate (<1.0% TFA) | Amber Glass or Poly Bottles | $28 – $40 / gram | 10 – 14 Working Days |
| Commercial Intermediate | 500g – 2,000g | ≥ 99.0% | Pure Acetate (<0.1% TFA) | Double Poly-lined Vacuum Drums | $14 – $22 / gram | 2 – 3 Weeks |
| Multi-Kilogram API | 5kg – 50kg+ | ≥ 99.0% (cGMP Grade) | Pure Pharmaceutical Acetate | Validated Cold-Chain Sealed Drums | $8 – $13 / gram | Custom Campaign Planning |
| Custom CDMO Formulation | Batch Dependent | Custom Specification | Pre-Formulated / Ready-to-Fill | Aseptic Vials (10mg/vial, 20mg/vial) | Contract Quotation | Per Milestone Schedule |
Increasing purity from 95% to ≥99.0% requires multiple passes through semi-preparative C18 reverse-phase columns (RP-HPLC). This process strips closely eluting deletion sequences (des-Pro or des-Gly fragments), directly influencing active substance yield and final unit cost.
For parenteral applications, sterile processing and depyrogenated water systems are mandatory to guarantee bacterial endotoxin levels <0.05 EU/mg. Endotoxin screening via Limulus Amebocyte Lysate (LAL) testing is embedded into each batch certificate.
Acetate salt conversion demands secondary ion-exchange resins and volumetric buffer flushes. Thinheal provides full salt characterization by ion chromatography (IC), verifying complete acetate stoichiometry and removing halogen residues.
How upstream amino acid integration, multi-ton peptide reactors, and strategic clustering deliver unmatched supply resilience and cost-efficiency.
Western and Indian CDMOs frequently face critical reagent bottlenecks, as raw Fmoc-protected amino acids, coupling additives (Oxyma, DIC, PyBOP), and specialty solid resins originate predominantly from Chinese manufacturers.
Located in Phase 5, Heda Medicine Valley, Qiantang District, Hangzhou, Thinheal sits directly at the nexus of the world's most dense biochemical manufacturing corridor. We maintain dedicated supply covenants with primary chemical synthesis plants, eliminating raw material allocation delays and shielding clients from global market price spikes.
Transitioning from 5-liter laboratory glass reactors to commercial 500-liter and 1000-liter automated solid-phase synthesis vessels requires strict control over solvent flow dynamics, heat dissipation during TFA cleavage, and resin swelling ratios.
Thinheal’s production base utilizes distributed control systems (DCS) to govern automated cycle times, washing iterations, and reagent dosages. This engineering automation cuts solvent consumption by 32%, raises batch-to-batch yield reproducibility to >96%, and provides multi-ton annual capacity across generic and therapeutic peptides.
Peptide manufacturing is heavily dependent on experienced chemical operators who understand cleavage kinetics and resin fouling dynamics. The leadership core at Thinheal brings nearly two decades of senior biopharmaceutical expertise.
Surrounded by leading scientific institutions (Zhejiang University, China Pharmaceutical University hubs), our analytical departments deploy multi-stage Mass Spectrometry (ESI-MS/MALDI-TOF), high-field NMR, and Karl Fischer titrations to ensure that every export lot complies with rigorous internal quality specifications.
Meeting the stringent quality release documentation demanded by FDA, EMA, NMPA, and international pharmacopeias.
Every commercial batch of Selank is supplied with a comprehensive Certificate of Analysis (CoA) containing individual impurity breakdowns. In accordance with ICH Q3A/B guidelines, any related substance exceeding 0.10% is identified, quantified, and cross-referenced with synthetic deletion libraries.
Dossier packages include high-resolution HPLC chromatograms showing gradient retention times, ESI-MS molecular mass confirmation (theoretical: 751.9 g/mol, observed: [M+H]+ = 752.9 ± 0.5 Da), amino acid stoichiometric ratios, and residual solvent residual profiling via Headspace GC (ICH Q3C).
To guarantee shelf-life integrity during global maritime or air transit, Thinheal conducts accelerated and long-term stability testing in compliance with ICH Q1A(R2) standards. Real-time testing at 25°C ± 2°C / 60% RH ± 5% RH and accelerated testing at 40°C ± 2°C / 75% RH ± 5% RH are cataloged.
Our data verifies that lyophilized Selank powder maintains ≥98.5% purity when kept sealed at -20°C for 24 months, with total degradation remaining below 0.8% under continuous refrigerated conditions (2°C – 8°C).
Navigating global customs clearance for biological materials requires meticulous tariff harmonization and customs documentation. Thinheal maintains dedicated regional regulatory sales desks to ensure compliance with local trade controls:
Analyzing market shifts toward nootropic peptides, neuro-immunology therapies, and next-generation delivery platforms.
Traditional benzodiazepine therapeutics carry severe clinical liabilities: sedation, motor impairment, tolerance, and physical dependence. As global neurological research targets safer alternatives, Selank has emerged as a premier synthetic candidate.
Because Selank acts as an allosteric modulator of GABA-A receptors and elevates brain-derived neurotrophic factor (BDNF) expression without inducing withdrawal, pharmaceutical formulators in Europe, the Americas, and Asia are integrating Selank into next-generation neuro-rehabilitation and stress-adaptation pipelines.
Subcutaneous injection remains an obstacle for patient compliance in chronic cognitive or anxiolytic therapies. A major procurement trend among global contract sponsors is the demand for peptide APIs optimized for non-invasive intranasal delivery.
Intranasal administration of Selank circumvents the blood-brain barrier via direct olfacto-trigeminal axonal pathways. Thinheal assists formulation teams with specialized micro-milling, spray-drying, and sterile liquid formulation development to maintain spray droplet uniformity and nasal mucosal absorption.
To combat short in-vivo half-lives driven by endogenous peptidases, peptide engineering is advancing toward N-terminal acetylation, C-terminal amidation, lipid conjugation (fatty diacid acylation similar to semaglutide models), and PEGylation.
Our R&D center works directly with innovative biotechnology firms to synthesize modified Selank analogues, evaluating enzyme-resistance profiles and prolonged pharmacokinetics across customized CRO research engagements.
Translating synthetic purity into verifiable neurological and immunological performance across diverse scientific settings.
In clinical pharmacology studies, Selank exhibits anxiolytic efficacy comparable to low-dose medazepam but without sedative or myorelaxant side effects. It modulates enkephalin degradation by inhibiting carboxypeptidase H and enkephalinase enzymes, sustaining endogenous opioid peptide activity during acute mental strain.
Selank significantly upregulates mRNA expression of BDNF and its high-affinity receptor TrkB in the hippocampus and frontal cortex. This neurotrophic activation promotes synaptogenesis, long-term potentiation (LTP), and information storage, making it a critical research tool for age-related cognitive decline.
Because Selank carries the active sequence of Tuftsin, it binds to specific macrophage and granulocyte receptors, stimulating phagocytic activity and natural killer (NK) cell proliferation. In neuroinflammatory conditions, it regulates balance between pro-inflammatory (IL-6, TNF-α) and anti-inflammatory cytokines.
Essential technical, analytical, and supply chain answers for pharmaceutical procurement directors and peptide researchers.
Net peptide content refers to the actual weight percentage of pure Selank peptide chains relative to the total lyophilized mass, which includes bound counter-ions (acetate or trifluoroacetate) and residual hygroscopic water. Standard high-grade Selank powder features a net peptide content ranging from 80.0% to 88.0%. We quantify this via quantitative Elemental Nitrogen Analysis (CHN) or Amino Acid Analysis (AAA) coupled with Karl Fischer water determination.
Trifluoroacetate ions can disrupt cellular respiration, inhibit enzyme functions, and alter blood pressure dynamics in animal models. When evaluating neurological endpoints such as anxiolysis or BDNF induction, residual TFA introduces experimental variability. Our pure acetate salt form guarantees TFA residues <0.1% w/w, meeting international pharmacopeia monographs and safeguarding biological validity.
Lyophilized Selank is packed in heavy-walled pharmaceutical borosilicate glass vials or double heat-sealed vacuum aluminum pouches flushed with dry inert argon gas. For international express shipping (FedEx, DHL, air cargo), shipments are packed with certified gel packs or dry ice blocks in insulated VIP containers, coupled with electronic USB/NFC continuous temperature data loggers.
Yes. In addition to supplying bulk raw API powder, Thinheal operates an end-to-end CDMO platform. We support N-terminal modifications, isotopic labeling for pharmacodynamic tracking, pegylation, and aseptic fill-finish manufacturing (liquid or lyophilized vials) within ISO Class 5 cleanroom suites, accompanied by complete batch manufacturing records (BMR).
Standard commercial delivery includes the Lot-Specific Certificate of Analysis (CoA), Analytical Method Validation summaries, RP-HPLC purity traces, High-Resolution ESI-MS or MALDI-TOF mass spectra, Residual Solvent screening reports (Headspace GC), Heavy Metals and Elemental Impurity reports (ICP-MS, ICH Q3D), and a formal Material Safety Data Sheet (MSDS/SDS).
Explore additional high-demand metabolic agonists, anti-anxiety peptides, and custom synthetic sequences from Thinheal's multi-ton manufacturing base.
Engage directly with Hangzhou Thinheal Pharma-Tech's technical chemistry team. Receive detailed COAs, comprehensive impurity profiles, and customized commercial pricelists within 24 business hours.
Thin